Capstone Therapeutics Corp.

CAPS Basic Materials Building Materials

Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.

0.09 0.01 −10.00%
Market cap
$2.7M
P/E
0.0×
Fwd P/E
5.3×
Dividend yield
—
F-score
3/9
Altman Z
−5.67
Beneish M
−3.81
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
19.11 23.00 25.98 26.86
Total non-current assets
39.37 28.38 27.82 27.82
Total Assets
58.48 51.38 53.80 54.68
Total current liabilities
20.02 22.92 27.43 27.11
Total non-current liabilities
11.31 16.00 15.15 15.15
Total liabilities
31.33 38.93 42.57 42.26
Common Equity (Total)
25.19 12.42 11.19 12.39
Shareholders Equity (Total)
27.16 12.45 11.22 12.42
Total Debt
19.22 23.36 25.87 25.46

Show all line items

In millions of $ except per-share values · columns are period end dates